NUFORMIX PLC
NFX | IL
Overview
Corporate Details
- ISIN(s):
- GB00BYW79Y38
- LEI:
- 2138003XG3H3I2J3BJ24
- Country:
- United Kingdom
- Address:
- 6TH FLOOR, EC3V 0HR LONDON
- Website:
- https://www.nuformix.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Nuformix PLC develops novel pharmaceutical products using proprietary cocrystal technology, focusing on oncology and fibrosis treatments in the UK.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for NUFORMIX PLC.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-11 08:00 |
Legal Proceedings Report
US FDA ODD Application Submitted for NXP002
|
English | 13.5 KB | |
| 2025-05-29 08:00 |
Regulatory News Service
Confirmation of European ODD for NXP002
|
English | 13.6 KB | |
| 2025-05-28 11:28 |
Prospectus
Nuformix plc - Single prospectus
|
English | 866.5 KB | |
| 2025-05-23 14:19 |
Prospectus
Prospectus
|
English | 866.5 KB | |
| 2025-05-23 14:08 |
Report Publication Announcement
Publication of a Prospectus
|
English | 13.3 KB | |
| 2025-02-28 13:30 |
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
|
English | 9.3 KB | |
| 2025-02-14 15:18 |
Report Publication Announcement
Posting of Annual Report and Notice of AGM
|
English | 8.4 KB | |
| 2025-01-30 08:00 |
Share Issue/Capital Change
£168,750 Placing
|
English | 13.1 KB | |
| 2025-01-29 08:00 |
Annual / Quarterly Financial Statement
Annual Results for period ended 30 September 2024
|
English | 414.7 KB | |
| 2025-01-28 08:00 |
Regulatory News Service
NXP002 ODD Application Submitted
|
English | 11.4 KB | |
| 2025-01-13 08:00 |
Regulatory News Service
NXP002 Orphan Drug Designation Draft Application
|
English | 9.6 KB | |
| 2024-11-29 18:00 |
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
|
English | 9.1 KB | |
| 2024-11-05 15:25 |
Director's Dealing
Director/PDMR Dealings
|
English | 39.9 KB | |
| 2024-11-04 11:17 |
Declaration of Voting Results & Voting Rights Announcements
Result of General Meeting
|
English | 21.2 KB | |
| 2024-10-18 11:34 |
Prospectus
Nuformix plc - Single prospectus
|
English | 1.6 MB |
Automate Your Workflow. Get a real-time feed of all NUFORMIX PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for NUFORMIX PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
ANIMALCARE GROUP PLC | United Kingdom | ANCR | |
|
Annexin Pharmaceuticals AB | Sweden | ANNX | |
|
Apontis Pharma AG | Germany | APPH | |
|
Aptahem AB | Sweden | APTA | |
|
Arctic Bioscience | Norway | ABS | |
|
ArcticZymes Technologies | Norway | AZT | |
|
argenx SE | Netherlands (Kingdom of the) | 1AE | |
|
ARIX BIOSCIENCE PLC | United Kingdom | ARIX | |
|
AroCell AB | Sweden | AROC | |
|
Arterra Bioscience | Italy | ABS |